



PARIS PSVD MEETING

DECEMBER 04TH AND 05TH



Organizing committee
Laure Elkrief,
Virginia Hernandez-Gea,
Pierre-Emmanuel Rautou

*Conservatoire National des Arts et Métiers (CNAM)
292 rue Saint Martin, 75003 Paris*

Day 1: COST EURO-VALDI-NET meeting PSVD

Current knowledge and future directions for PSVD

8H30
-
8H35 | *Opening and introductory words*

8H35
-
9H00 | *Feed-back from the Paris nomenclature meeting*
Virginia HERNANDEZ-GEA - Spain

9H05
-
11H05 | *Session 1: Pathophysiology
and conditions associated with PSVD*

Moderators: Bogdan PROCOPET - Romania

*1/ Conditions associated with PSVD; impact on prognosis and
impact of their treatment on PSVD*

Filipe NERY - Portugal

2/ Genetics and PSVD

Silvia VILARINHO - USA

*3/ Pathophysiology: is PSVD an immune, a vascular or a
coagulation disorder?*

Marco SENZOLO - Italy

4/ Preclinical models of PSVD

Genís CAMPRECIÓS - Spain

11H05
-
11H30 | *Coffee Break*

11H30
-
12H50

Session 2: Diagnosis and Natural history of PSVD

Moderators: Nicola PUGLIESE - Italy, Sarah RAEVENS - Belgium

1/ When should PSVD be suspected?

Laure ELKRIEF - France

2/PSVD without portal hypertension

Pierre DELTENRE - Belgium

3/ Prognostic and natural history of PSVD with signs of portal hypertension

Juan-Carlos GARCIA-PAGAN - Spain

12H50
-
14H00

Lunch Break

14H00
-
15H00

Session 3: Diagnostic tools in PSVD

Moderators: Katharina LAMPICHLER - Austria, Valérie PARADIS - France

1/ Imaging and PSVD: how to improve diagnosis and prognostic?

Maxime RONOT - France

2/ Pathological changes in PSVD: current view and future directions

Valérie PARADIS - France, Alexandre Sayadi - France

15H00

-

16H10

Session 4: Challenges in PSVD

Moderators: Bernhard SCHEINER - Austria, Akash Shukla - India

1/ Can PSVD regress?

Andrea DE GOTTARDI - Switzerland

2/ Can PSVD lead to cirrhosis?

Theo HELLER - USA

3/ Nodules in PSVD

Christine SEMPOUX - Switzerland

16H10

-

16H40

Coffee Break

16H40

-

18H40

Session 5: Management of PSVD

Moderators: Necati ÖRMECI - Turkey, Annalisa BERZIGOTTI - Switzerland

1/ Hemodynamic changes in PSVD and their modulation

Lucile MOGA - France

2/ Management of complications of portal hypertension in PSVD: should that really be the same as in cirrhosis?

Michael PRAKTIKNJO - Germany

3/ Liver transplantation in PSVD

Sarwa DARWISH-MURAD - Netherlands

4/ Specificities of PSVD in children and transition to adulthood

Angelo DI GIORGIO - Italy

18H30

Concluding remarks

Day 2: FILFOIE-ERN PSVD meeting*Consensus statement on clinical trials in PSVD*

09H00**-****11H00*****Session 1: Break out session on clinical trials in PSVD***

Moderator: Laure ELKRIEF - France

1/ Inclusion criteria for studies on PSVD

Juan-Carlos GARCIA-PAGAN - Spain, Aurélie PLESSIER - France, Andréa DE GOTTARDI - Switzerland, Maxime RONOT - France, Christine SEMPOUX - France, Luis TÉLLEZ - Spain, Emmanuel GONZALES - France, Raymundo PARANA - Brasil, Moira HILSCHER - USA

Moderator: Pierre-Emmanuel RAUTOU - France

2/ Surrogate markers of outcome in PSVD: do's and don'ts

Elton DAJTI - Italy, Annalisa BERZIGOTTI - Switzerland, Necati ÖRMECI - Turkey, Eira CERDA - Mexico, Laura TURCO - Italy, Fanny TURON - Spain, Akash SHUKLA - India, Ansgar LOHSE - Germany, Anna BAIGES - Spain, Valérie PARADIS - France, Maxime RONOT - France, Lucile MOGA - France

Moderator: Virginia HERNANDEZ-GEA - Spain

3/ Hard endpoints in PSVD studies

Christophe BUREAU - France, Jonel TREBICKA - Germany, Dominique VALLA - France, Sarwa DARWISH MURAD - Netherlands, Dhiraj TRIPATHI - UK, Angela PUENTE - Spain, Elisabeth VERNA - USA, Marco SENZOLO - Italy

11H00**-****11H30*****Coffee Break***

11H30
-
12H30

Session 2: Innovations for clinical trials in PSVD

Moderator: Dhiraj TRIPATHI - UK, Moira HILSCHER - USA

1/ Innovative trial design for rare diseases

Lucie BIARD - France

2/ HRQOL and PRO in patients with PSVD

Agnès DUMAS - France, Aurélie PLESSIER - France, Patient representative

12H30
-
13H30

Lunch Break

13H30
-
15H30

Session 3

Moderator: Marco SENZOLO - Italy, Audrey PAYANCE - France

1/ Novel therapies and therapeutic approaches

Pierre-Emmanuel RAUTOU - France

2/ Feed-back from the working groups

a/ Inclusion criteria for studies on PSVD

Laure ELKRIEF - France

b/ Surrogate markers of outcome in PSVD: do's and don'ts

Pierre-Emmanuel RAUTOU - France

c/ Hard endpoints in PSVD studies

Virginia HERNANDEZ-GEA - Spain

15H30
-
16H00

Wrap-Up

Thanks to our scientific partners



MALADIES RARES DU FOIE
DE L'ADULTE ET DE L'ENFANT

FILIÈRE DE SANTÉ

